Company Filing History:
Years Active: 2025
Title: The Innovations of Peter Peizhi Luo
Introduction
Peter Peizhi Luo is a notable inventor based in Suzhou, China. He has made significant contributions to the field of immunology through his innovative research and development of therapeutic antibodies. His work focuses on enhancing T-cell function, which is crucial for effective immune responses.
Latest Patents
Peter Peizhi Luo holds a patent for "Anti-CD137 molecules and use thereof." This patent provides antibodies that bind to human CD137 or antigen-binding fragments. It also includes nucleic acid encoding the same, therapeutic compositions, and their applications in enhancing T-cell function. This innovation is particularly relevant for treating T cell dysfunctional disorders, such as tumor immunity and cancer.
Career Highlights
Peter is currently associated with Adagene Inc., a company dedicated to advancing antibody-based therapies. His work at Adagene has positioned him as a key player in the development of novel immunotherapeutic strategies.
Collaborations
Peter has collaborated with notable colleagues, including Fangyong Du and Yan Li. These partnerships have further enriched his research and contributed to the advancement of their shared goals in immunology.
Conclusion
Peter Peizhi Luo's innovative work in the field of immunology, particularly through his patent on Anti-CD137 molecules, showcases his commitment to enhancing cancer treatment and immune response. His contributions are paving the way for future advancements in therapeutic applications.